Predicting IVF Outcomes with Serum AMH Levels in Older Patients
Author Information
Author(s): Lee Robert KK, Wu Frank SY, Lin Ming-Huei, Lin Shyr-Yeu, Hwu Yuh-Ming
Primary Institution: Mackay Memorial Hospital, Taipei, Taiwan
Hypothesis
Can serum anti-Müllerian hormone (AMH) levels combined with biological age predict IVF outcomes for patients of advanced reproductive age?
Conclusion
Serum AMH levels in conjunction with age can help identify IVF candidates at risk of poor outcomes.
Supporting Evidence
- Patients with AMH levels in the low tertile had a 47.6% cycle cancellation rate and zero clinical pregnancies.
- The nadir AMH level that achieved live birth was 0.56 ng/mL.
- Optimal cut-off levels of AMH for predicting nonpregnancy and cycle cancellation were 1.05 and 0.68 ng/mL, respectively.
Takeaway
Doctors can use a blood test to check a hormone called AMH to see if older women might have a hard time getting pregnant with IVF.
Methodology
The study analyzed medical records of 116 infertile patients aged 40 and above who underwent IVF/ICSI, comparing their AMH levels and cycle outcomes.
Potential Biases
Potential biases may arise from the retrospective nature of the study and the specific population targeted.
Limitations
The study had a relatively small sample size and was retrospective, which may limit the generalizability of the findings.
Participant Demographics
Infertile patients aged 40 years and older, with a total of 116 participants.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% confidence interval for clinical pregnancies from low to high tertile was zero to 16 percent, 13-39 percent, and 19-42 percent respectively.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website